Abstracts tagged "fibrosis and systemic sclerosis"

Abstract Number: 1704 • 2014 ACR/ARHP Annual Meeting
CXCL4 Promotes Fibrosis By Increasing Expression of Extracellular Matrix Modifying Factors and By Facilitating Epithelial/Endothelial Mesenchymal Transition
W. Marut¹, A.J. Affandi¹, A. Limpers¹ and T.R.D.J. Radstake², ¹Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose Systemic sclerosis (SSc) is a degenerative disorder, characterized by vascular abnormalities and immunological disturbances followed by excessive fibrosis in multiple organ systems. In a…
Abstract Number: 966 • 2014 ACR/ARHP Annual Meeting
Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism
Feng Fang¹, Roberta G. Marangoni¹, Xingchun Zhou², Wen Hong³, Boping Ye³, Asano Yoshihide⁴, Shinichi Sato⁵, Yuri Masui⁶, Chengning Zhang⁷, Katja Lakota⁸, Jun Wei⁹, Monique E. Hinchcliff⁷, Philipp Scherer¹⁰, Laszlo Otvos¹¹ and John Varga¹², ¹Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ²College of Life and Science, China Pharmaceutical University, Nanjing, China, ³China Pharmaceutical University, Nanjing, China, ⁴University of Tokyo, Tokyo, Japan, ⁵Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan, ⁶Department of Dermatology, University of Tokyo, Tokyo, Japan, ⁷Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁸Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁹Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Texas Southwestern Medical Center, Dallas, TX, ¹¹Temple University, Philadelphia, PA, ¹²Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose :Systemic sclerosis (SSc) skin fibrosis is associated with attenuated cutaneous adipose tissue and adipogenic gene expression. Levels of the adipose-derived cytokine adiponectin (APN) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].